Molecular Pharmaceutics · 2024 · 15 citations · 63 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint RegulationOvarian CancerOvarian ImmunologyImmune Checkpoint Combination TherapyImmune Checkpoint Inhibitor TherapyImmunotherapy For Ovarian CancerOvarian Cancer Clinical TrialsOvarian Cancer ImmunologyOvarian Cancer TreatmentRandomized Clinical TrialsTranslational Immuno-oncology
Ovarian cancer, one of the deadliest malignancies, lacks effective treatment, despite advancements in surgical techniques and chemotherapy. Thus, new therapeutic approaches are imperative to improving treatment outcomes. Immunotherapy, which has demonstrated considerable success in managing various cancers, has already found its place in clinical practice. This review aims to provide an overview of ovarian tumor immunotherapy, including its basics, key strategies, and clinical research data supporting its potential. In particular, this discussion highlights promising strategies such as checkpoint inhibitors, vaccines, and pericyte transfer, both individually and in combination. However, the advancement of new immunotherapies necessitates large controlled randomized trials, which will undoubtedly shape the future of ovarian cancer treatment.
63
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · New England Journal of Medicine · 2020 · 3K citations · Full text
Medicine, Oncology, Pharmacology +17
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Răzvan Cristescu, Robin Mogg, Mark Ayers et al. · Science · 2018 · 2.3K citations
Medicine, Immunology, Oncology +17
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity
Tyler J. Curiel, Shuang Wei, Haidong Dong et al. · Nature Medicine · 2003 · 1.3K citations
Life Sciences, Immunology, Oncology +15